Evidence map›Paper›PMID 40852769›Full record

ArticleAdvanced healthcare materials2025

Using High-Throughput Screening to Identify Crosslinking Peptides That Control Cell-Mediated Matrix Degradation.

Yingjie Wu, Samuel J Rozans, Abolfazl Salehi Moghaddam, E Thomas Pashuck

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yingjie WuLehigh University, 124 E. Morton Street, Bethlehem, Pennsylvania, 18015, United States of America.
Samuel J RozansLehigh University, 124 E. Morton Street, Bethlehem, Pennsylvania, 18015, United States of America.
Abolfazl Salehi MoghaddamLehigh University, 124 E. Morton Street, Bethlehem, Pennsylvania, 18015, United States of America.
E Thomas PashuckLehigh University, 124 E. Morton Street, Bethlehem, Pennsylvania, 18015, United States of America.ORCID 0000-0003-2881-4965

Funding

Designing technologies to visualize protease activity in cancer modelsR21GM143593 · NIGMS · LEHIGH UNIVERSITY · PI PASHUCK, EUGENE THOMAS · 2021 to 2022
$408k
NIGMS NIH HHS R21 GM143593
6 · The paper itself

Abstract

Cells modify the extracellular matrix by expressing proteases that degrade matrix proteins, enabling cell migration within tissues. This process is mimicked in hydrogels through protease-degradable peptide crosslinks. However, cleaving hydrogel crosslinks reduces local matrix mechanical properties, and most crosslinking peptides, including the widely used GPQGIWGQ "PanMMP" sequence, often lead to bulk hydrogel degradation. Membrane-type proteases are localized to the cell surface, have important roles in cell migration, and are active in the pericellular region. To identify peptides primarily cleaved by membrane-type proteases, an approach is developed that couples proteomic identification of candidate peptides with mass spectrometry-based functional assays to quantify degradation. The target sequence is then optimized using a split-and-pool synthesis to generate over 300 peptide variants to improve degradation behavior. The optimized peptide, KLVADLMASAE, shows reduced degradation by soluble proteases, while enabling endothelial and stem cell spreading and viability comparable to PanMMP hydrogels. KLVADLMASAE-crosslinked hydrogels have reduced crosslinker degradation, are stiffer during culture, and exhibit less macroscopic degradation after 14 days of culture than PanMMP gels. The performance of KLVADLMASAE-crosslinked gels is significantly improved from the initial peptide target, validating this functional high-throughput approach for identifying peptides that control matrix degradation.

Indexed as

Cross-Linking ReagentsExtracellular MatrixHigh-Throughput Screening AssaysPeptidesHumansHydrogelsCross-Linking ReagentsHydrogelsPeptidescell‐matrix interactionsendothelial cellshigh‐throughputhydrogelsmesenchymal stem cellsproteases

Identifiers

PMID40852769
PMCPMC12683216

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.